BioLineRx Ltd.

MODI'IN, L3 · Biotech · Private

Monoclonal antibody and small molecule therapeutics for cancer and rare diseases

Claim this profile

Follows are private to you and power your alerts

Updated · biolinerx.com

Sector
Biotech
Headquarters
MODI'IN, L3
Latest Form D
$3.8M, Sep 2026
Total capital
$17.1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$17.1M
3 Form D · last Sep 2026
2 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
14
22 pending · first 2020
Rank in peer group#122 of 1449

Capital timeline

2020202120222023202420252026FEDERAL ↑EQUITY ↓Cumulative $17.1M1st Form D$9M3rd Form D$3.8M
2020202220242026FEDERAL ↑EQUITY ↓Cumulative $17.1M1st Form D$9M3rd Form D$3.8M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$3.8M
  • Private capital raisedForm D · SEC · 2nd filing$4.4M
  • Private capital raisedForm D · SEC · 1st filing$9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#122 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Abi A. Vainstein-HarasExecutive OfficerNamed in SEC Form D filings
  • Aharon SchwartzDirectorNamed in SEC Form D filings
  • Avraham Jean MolchoDirectorNamed in SEC Form D filings
  • Barbara Jean BormannDirectorNamed in SEC Form D filings
  • Ella A. SoraniExecutive OfficerNamed in SEC Form D filings
  • Mali A. ZeeviExecutive OfficerNamed in SEC Form D filings
Show all 11 people
  • Michael J. AnghelDirectorNamed in SEC Form D filings
  • Nurit J. BenjaminiDirectorNamed in SEC Form D filings
  • Philip A. SerlinExecutive OfficerNamed in SEC Form D filings
  • Raphael Jean HofsteinDirectorNamed in SEC Form D filings
  • Sandra Jean PanemDirectorNamed in SEC Form D filings

What it has protected

USPTO · 14 granted of 36
Show all 36 patent records
  • Process For Manufacturing PeptideMay 28, 2024 · US 11,993,631Granted
  • Compositions And Methods For Treating CancerMay 16, 2023 · US 11,648,293Granted
  • Compositions And Methods For Treating CancerMay 9, 2023 · US 11,642,393Granted
  • Compositions And Methods For Treating CancerMay 2, 2023 · US 11,638,742Granted
  • Compositions And Methods For Treating CancerMay 2, 2023 · US 11,638,743Granted
  • CXCR4 Inhibitor For The Treatment Of Acute Respiratory Distress Syndrome And Viral InfectionsApr 6, 2023 · Application 17910364Pending
  • Compositions And Methods For Treating CancerMar 28, 2023 · US 11,612,638Granted
  • Compositions And Methods For Treating CancerMar 21, 2023 · US 11,607,444Granted
  • Compositions And Methods For Treating CancerMar 7, 2023 · US 11,596,666Granted
  • Compositions And Methods For Treating CancerFeb 28, 2023 · US 11,590,200Granted
  • Compositions And Methods For Treating CancerJan 24, 2023 · US 11,559,562Granted
  • Compositions And Methods For Treating CancerJan 17, 2023 · US 11,554,159Granted
  • Compositions And Methods For Treating CancerDec 27, 2022 · US 11,534,478Granted
  • CXCR4 Inhibitor For The Treatment Of Acute Respiratory Distress Syndrome And Viral InfectionsSep 15, 2022 · Application 17827832Pending
  • AGI-134 Combined With A Checkpoint Inhibitor For The Treatment Of Solid TumorsApr 29, 2021 · Application 17056803Pending
  • Compositions, Articles Of Manufacture And Methods For Treating CancerDec 17, 2020 · Application 17006954Pending
  • Compositions, Articles Of Manufacture And Methods For Treating CancerSep 29, 2020 · US 10,786,547Granted
  • Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866627Pending
  • Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866641Pending
  • Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866615Pending
  • Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866609Pending
  • Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866640Pending
  • Compositions And Methods For Treating CancerSep 3, 2020 · Application 16866671Pending
  • Compositions And Methods For Treating CancerAug 27, 2020 · Application 16866603Pending
  • Compositions And Methods For Treating CancerAug 27, 2020 · Application 16866658Pending
  • Compositions And Methods For Treating CancerJun 16, 2020 · US 10,682,390Granted
  • Methods Of Treating Acute Myeloid Leukemia With A FLT3 MutationFeb 7, 2019 · Application 16163605Pending
  • Methods Of Treating Myeloid LeukemiaDec 6, 2018 · Application 16049898Pending
  • Methods Of Treating Myeloid LeukemiaNov 1, 2018 · Application 16035790Pending
  • CXCR4 Binding Agents For Treatment Of DiseasesAug 9, 2018 · Application 15749558Pending
  • Methods Of Obtaining Mononuclear Blood Cells And Uses ThereofJun 14, 2018 · Application 15571069Pending
  • Methods Of Mesenchymal Stem Cell Mobilization And ExpansionMay 24, 2018 · Application 15570389Pending
  • Methods Of Treating Acute Myeloid Leukemia With A FLT3 MutationAug 25, 2016 · Application 15027252Pending
  • Methods Of Treating Myeloid LeukemiaMar 24, 2016 · Application 14771513Pending
  • Crystalline Forms Of The Tri-mesylate Salt Of Perphenazine-gaba And Process Of Producing The SameJun 13, 2013 · Application 13763815Pending
  • Methods Of Hematopoietic Precursor Cells MobilizationApplication 19469422Pending
  • Therabene Inc.Similar federal contract value in Biotech · null in contracts
  • Salve Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • RHEUMAGEN, INC.Similar federal contract value in Biotech · null in contracts
  • NANOPHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
  • Nerio TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Zafrens Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .